Elderly patients with diabetes experience a lower rate of nocturnal hypoglycaemia with insulin degludec than with insulin glargine: a meta-analysis of phase IIIa trials. - Wikidata - wikimedia - TriplyDB

Elderly patients with diabetes experience a lower rate of nocturnal hypoglycaemia with insulin degludec than with insulin glargine: a meta-analysis of phase IIIa trials.

Elderly patients with diabetes experience a lower rate of nocturnal hypoglycaemia with insulin degludec than with insulin glargine: a meta-analysis of phase IIIa trials.

http://www.wikidata.org/entity/Q37321746

about

Concentrated insulins: the new basal insulins Safety, efficacy, and early clinical experience of insulin degludec in Japanese people with diabetes mellitus: A first-year report from Japan Patient safety and minimizing risk with insulin administration - role of insulin degludec Optimal therapy of type 2 diabetes: a controversial challenge Achieving glycemic control in elderly patients with type 2 diabetes: a critical comparison of current options.The beneficial effect of insulin degludec on nocturnal hypoglycaemia and insulin dose in type 1 diabetic patients: a systematic review and meta-analysis of randomised trials.Ultra-long pharmacokinetic properties of insulin degludec are comparable in elderly subjects and younger adults with type 1 diabetes mellitus.Optimal glycaemic control in elderly people with type 2 diabetes: what does the evidence say?Clinical and cost-effectiveness of insulin degludec: from clinical trials to clinical practice.New Basal Insulins: a Clinical Perspective of Their Use in the Treatment of Type 2 Diabetes and Novel Treatment Options Beyond Basal Insulin.Pursuit of a perfect insulin.Degludec: the new ultra-long insulin analogue.Steady state is reached within 2-3 days of once-daily administration of degludec, a basal insulin with an ultralong duration of action.

P2860

Q26750438-03AF617D-669D-451B-B864-AB38C0254E19 Q26778763-91A8E849-F8B0-4C25-B755-EEB60DDEBC79 Q27025548-77C3EA02-DFE9-4CFB-948F-A1047C9BC9A0 Q33577712-F29CA4CD-C7D2-4E0B-A9C4-7DFA1760B6DB Q34563587-66AD9AA3-599F-426C-B922-91C10FC187CA Q35457098-6D205039-B337-473F-86BA-6873FA4FF64F Q37432141-49D0BE4C-8860-4037-A4DC-EB945442AB52 Q38284244-B9948013-CDD7-412F-8BF4-4EBE3CAE6F76 Q38470334-BBE8E0BC-1860-4331-946C-4D8C36B20CEF Q38640170-918D5551-9903-4183-A824-77D89F1089AA Q38778988-989F8E9C-34D7-4134-A238-A0115EAD7B2F Q41564970-B2912BA4-B59A-446F-8320-59917D0F031B Q46358093-83921538-8334-40E2-A986-2DC666006B2D

P2860

Elderly patients with diabetes experience a lower rate of nocturnal hypoglycaemia with insulin degludec than with insulin glargine: a meta-analysis of phase IIIa trials.

http://www.wikidata.org/entity/Q37321746

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on December 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Elderly patients with diabetes ...... analysis of phase IIIa trials.

@en

Elderly patients with diabetes ...... analysis of phase IIIa trials.

@nl

type

label

Elderly patients with diabetes ...... analysis of phase IIIa trials.

@en

Elderly patients with diabetes ...... analysis of phase IIIa trials.

@nl

prefLabel

Elderly patients with diabetes ...... analysis of phase IIIa trials.

@en

Elderly patients with diabetes ...... analysis of phase IIIa trials.

@nl

P1433

Q37321746-79AF19AA-E668-446B-94AC-48248B8AB9B5

P1476

Q37321746-0BE443DC-7ABE-45D4-8EC1-F835E8167F34

P2093

Q37321746-1B80BD82-4C6E-4ADC-8676-329B41D76BF2

Q37321746-4FE68F08-10A6-445D-B23B-A785F95606D6

Q37321746-69652538-DCBA-4E54-BFB1-963FA8C89EA2

Q37321746-A66473B7-3B21-43DA-9DD9-1F045F441BFB

Q37321746-FCC74AE0-C7DF-4108-9FB4-3D30ACAB53A6

Q37321746-FD7070CF-FB55-4447-9770-84DD9F9FD4DC

P2860

Q37321746-070D1195-BC83-4807-AA15-6232234A5334

Q37321746-2FEF19DC-D461-4045-9C12-216D2118E4C3

Q37321746-32A0F1E2-7376-4E76-A369-E0ADD5448656

Q37321746-383BE05E-DEC4-430D-84F1-7C4AF5F0D3CF

Q37321746-5434F077-031E-49E9-AAAE-9682825F3CE3

Q37321746-5B8A9660-9D54-4BCA-9047-0C23968DD057

Q37321746-6A9F4133-4D37-48A8-BCC4-1B3008B9BC45

Q37321746-6ECBE0E9-C0AB-4599-A509-31A0A8FF9B7C

Q37321746-70C4173F-CE05-43B9-ACAC-A4692EA5BB78

Q37321746-761BA947-2AC4-4480-9072-2CFA74C72683

P2888

Q37321746-F28965DD-C8D3-411C-8888-971D5237D29A

P304

Q37321746-271BF3B4-6B25-45E8-A22D-DBE14E857B33

P31

Q37321746-D7A0511C-5A9C-486A-A427-0DA73CDDCAF1

Q37321746-e4c285f1-4dc9-46bc-a9a5-f2e8727b86a9

P356

Q37321746-BB1CD2A8-BF22-4B4D-A4D7-8D65B1B6D66C

P433

Q37321746-A5F68DFD-4307-49CF-9A75-E2A130AC37AE

P478

Q37321746-79FD4D90-57D9-435C-82A7-884FFB1AEA51

P577

Q37321746-BB70CCF6-14BE-4DEC-B030-3C9D8755CEF0

P5875

Q37321746-0CB88677-03C6-4902-A790-50524A223FFB

P698

Q37321746-8697725E-B3BE-4239-8BA0-90E34C138C7B

P921

Q37321746-2F2B1B0B-042E-4A31-B902-18FFAF903FED

Q37321746-7C2DFEE2-D12E-40B5-B0A0-9CC5F80E5F06

P932

Q37321746-C5117CE9-ECF6-4D23-901A-F244BB96FC8E

P356

S40266-013-0128-2

P1433

P1476

Elderly patients with diabetes ...... analysis of phase IIIa trials.

@en

P2093

Christopher Sorli

http://www.w3.org/2001/XMLSchema#string

David Oyer

http://www.w3.org/2001/XMLSchema#string

Henriette Mersebach

http://www.w3.org/2001/XMLSchema#string

Mark Warren

http://www.w3.org/2001/XMLSchema#string

Stephen C L Gough

http://www.w3.org/2001/XMLSchema#string

Thue Johansen

http://www.w3.org/2001/XMLSchema#string

P2860

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Standards of medical care in diabetes--2012

Diabetes in older adults

The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study.

Insulin degludec compared with insulin glargine in insulin-naïve patients with type 2 diabetes: A 26-week, randomized, controlled, Pan-Asian, treat-to-target trial.

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority tria

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority tria

Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes.

Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long)

Diabetes-related complications, glycemic control, and falls in older adults.

P2888

s40266-013-0128-2

P304

1009-1018

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40266-013-0128-2

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P577

2013-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258148123

http://www.w3.org/2001/XMLSchema#string

P698

24170235

http://www.w3.org/2001/XMLSchema#string

P921

P932

3832772

http://www.w3.org/2001/XMLSchema#string